Compare TG Therapeutics Inc (TGTX) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Williams-Sonoma, Inc. — how do they compare? TG Therapeutics Inc trades at $54.77 (market cap $8.53B), while Williams-Sonoma, Inc. trades at $228.08 (market cap $26.83B). The key difference: Williams-Sonoma, Inc. is far larger — about 3.1× TG Therapeutics Inc's market cap, and Williams-Sonoma, Inc. pays a 1.33% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | WSM | |
|---|---|---|
Market Cap | $8.53B | $26.83B |
Sector | Health | Consumer Cyclical |
52-Week High | $59.06 | $251.81 |
52-Week Low | $26.94 | $168.64 |
Enterprise Value | $8.74B | $27.33B |
Dividend Yield | — | 1.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Williams-Sonoma (WSM) trades at $227.83, up 0.18% on the day, with a bearish technical signal but strong fundamentals. The stock has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $2.10 exceeding expectations. Revenue growth of 6.2% in Q2 2026 reflects market share gains in a flat home furnishings industry, supported by a robust net income margin of 14.73% and ROE of 54.96%.
The outlook is positive given raised full-year guidance and analyst consensus price target of $252.62, though near-term risks include tariff pressures on margins and technical resistance near $231. Institutional buying, such as HSBC's 12.1% stake increase in Q2 2026, underscores confidence in continued execution amid competitive and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
